ALLHAT: Officers and Coordinators for the ALLHAT Collabo¬rative Research Group. JAMA, 288:2981–2997, 2002. ALLHAT: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major cardiovascular events in hypertensive patients randomized to doxazosin vs. chlorthalidone. The ALLHAT
vofficers and coordinators for the ALLHAT Collaborative Research Group. JAMA, 283:1967–1975, 2000.
ALLHAT: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic).
Black, M.D., H. R., Elliott, M.D., Ph.D., W. J., Grandits, G., Anders, Pharm.D., J., for the CONVINCE Research Group et al. Principal results of the controlled onset verapamil investigation of cardiovascular end points (CONVINCE) trial. JAMA, 289:2073–2082, 2003.
Blood Pressure Lowering Treatment Trialists Collaboration. Effects of different blood -pressure lowering regimens on major cardiovascular events: Results of prospectively-designed overviews of randomized trials. Lancet, 362:1527–1535, 2003.
Campbell, D. J. How should I combine beta blockers, ACE inhibitors and ARBs in the management of heart failure? JNC 7. The Seventh Report of the joint national committee on prevention detection evaluation and treatment of high blood pressure. NIH, NHLBI, May 2003.

Страницы: 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8